| abstract |
This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments. |